FY2030 Earnings Forecast for SANA Issued By HC Wainwright

Sana Biotechnology, Inc. (NASDAQ:SANA) – Stock analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Sana Biotechnology in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.49) per share for the year. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03).

A number of other brokerages also recently issued reports on SANA. Bank of America upped their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Zacks Research cut Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, Wedbush boosted their price objective on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Sana Biotechnology has an average rating of “Moderate Buy” and an average target price of $7.83.

Sana Biotechnology Stock Down 10.7%

Sana Biotechnology stock opened at $3.41 on Thursday. The firm has a market cap of $910.03 million, a PE ratio of -3.52 and a beta of 1.96. The company’s 50 day moving average is $4.27 and its two-hundred day moving average is $4.14. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $6.55.

Institutional Investors Weigh In On Sana Biotechnology

Several hedge funds have recently made changes to their positions in the company. Baillie Gifford & Co. grew its position in shares of Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after buying an additional 1,371,775 shares during the period. Corient Private Wealth LLC lifted its position in Sana Biotechnology by 264.7% in the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after acquiring an additional 824,505 shares in the last quarter. Marex Group plc purchased a new position in shares of Sana Biotechnology during the second quarter valued at approximately $10,423,000. Savant Capital LLC purchased a new position in Sana Biotechnology during the 2nd quarter worth $172,000. Finally, Good Life Advisors LLC bought a new stake in Sana Biotechnology in the 2nd quarter worth about $46,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.